[
    [
        {
            "time": "",
            "original_text": "【国盛医药张金洋团队】周观点：智飞生物研发管线有望获得市场重估，“销售+研发”双轮驱动",
            "features": {
                "keywords": [
                    "智飞生物",
                    "研发管线",
                    "市场重估",
                    "销售+研发",
                    "双轮驱动"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国盛医药张金洋团队】周观点：智飞生物研发管线有望获得市场重估，“销售+研发”双轮驱动",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]